SuperworthLyell Immunopharma shares outstanding LYEL
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 23.4M
- On a year earlier
- +57.9%
- more shares
Lyell Immunopharma had 23.4M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 57.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 20.5M | +46% |
| FY2024 | 14M | +11% |
| FY2023 | 12.6M | +1% |
| FY2022 | 12.5M | +4% |
| FY2021 | 12M | +1490% |
| FY2020 | 757.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 23.4M | +58% | |
| Q1 FY26 | 21.9M | +48% | |
| Q4 FY25 | 20.5M | +46% | |
| Q3 FY25 | 18.3M | +43% | |
| Q2 FY25 | 14.8M | +16% | |
| Q1 FY25 | 14.8M | +16% | |
| Q4 FY24 | 14M | +11% | |
| Q3 FY24 | 12.8M | +2% | |
| Q2 FY24 | 12.8M | +2% | |
| Q1 FY24 | 12.7M | +2% | |
| Q4 FY23 | 12.6M | +1% | |
| Q3 FY23 | 12.6M | +1% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Lyell Immunopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.